| Project/Area Number |
18K15286
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Tokyo Metropolitan Komagome Hospital (Clinical research laboratory) |
|---|
Principal Investigator |
Otani Ryohei 東京都立駒込病院(臨床研究室), 脳神経外科, 医長 (30786968)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | グリオーマ / 脳腫瘍 / genomics / 19q / サブグループ / Glioma / 遺伝子 |
|---|
| Outline of Final Research Achievements |
We previously reported that there was a subgroup of IDH-mutated astrocytomas harboring only 19q-loss showing better prognosis compared with 19q-intact astrocytomas. To further explore the biological mechanism of this subgroup, we compared gene expression pattern between 19q-loss and 19q-intact astrocytomas by microarray analysis. Multiple genes associated with stem cell maintenance and glioma progression were down-regulated in 19q-loss astrocytomas, and the expression pattern of the 19q-loss astrocytomas constituted a subgroup of astrocytoma. These findings suggested that 19q-loss in astrocytomas is acquired, and that the biological features are possibly related to differentially expressed genes associated with stem cell maintenance and glioma progression.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究の成果は、未だ予後不良な悪性脳腫瘍であるグリオーマの分類に新たなサブグループを提唱することで、今後のグリオーマにおける予後予測、治療戦略に大きな影響を与える。現在、星細胞腫の19qの状態は臨床において測定されていないが、本研究の結果は19q欠失の有無を同定する重要性を示しており、特に乏突起膠腫様の病理像を含む星細胞腫においては、遺伝学的に星細胞腫と同定されていても、19q欠失の有無を確認する必要性を示している。
|
